Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male or female at least 18 years of age~* Patients who are to initiate Exenatide treatment for type 2 diabetes at baseline, following their treating physicians' advice~* Patients, who in the opinion of the treating physicians, comply with all the recommendations stated in the relevant product information~Exclusion Criteria:~* Are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug~* Are pregnant or have intentions of becoming pregnant within the duration of the study~* Contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group1:Type 2 diabetic patients treated with Exenatide therapy (Type: None): Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label

Based on this trial design, predict the completion outcome and termination type (if applicable).